VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis
Vitamin K is necessary for the carboxylation of clotting factors and matrix Gla protein (MGP). Vitamin K epoxide reductase (VKOR) is the enzyme responsible for recirculation of Vitamin K increasing its tissue availability. Polymorphisms of VKOR may alter the function of MGP, thereby influencing vasc...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Saudi Journal of Kidney Diseases and Transplantation |
Online Access: | http://www.sjkdt.org/article.asp?issn=1319-2442;year=2016;volume=27;issue=5;spage=908;epage=915;aulast=Osman |
id |
doaj-cdb916b4cb3047dda918f43406e0a853 |
---|---|
record_format |
Article |
spelling |
doaj-cdb916b4cb3047dda918f43406e0a8532020-11-24T23:52:58ZengWolters Kluwer Medknow PublicationsSaudi Journal of Kidney Diseases and Transplantation1319-24422016-01-0127590891510.4103/1319-2442.190782VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysisNoha A OsmanNevine El-AbdMohamed NasrallahVitamin K is necessary for the carboxylation of clotting factors and matrix Gla protein (MGP). Vitamin K epoxide reductase (VKOR) is the enzyme responsible for recirculation of Vitamin K increasing its tissue availability. Polymorphisms of VKOR may alter the function of MGP, thereby influencing vascular calcification. We conducted this study to investigate the relationship of VKORC1 gene single nucleotide polymorphisms (SNP′s) to vascular calcification and clinically overt cardiovascular disease in chronic kidney disease (CKD) patients on hemodialysis (HD). The study included 54 CKD patients on HD. We excluded those with diabetes or on anticoagulant therapy. Vascular calcifications were measured using computerized tomography scans and roentgenograms. Prevalent clinically overt cardiovascular disease was reported based on the evidence of documented preexisting major cardiovascular events. Genotype detection for the gene VKORC1 C1173T and G-1639A polymorphisms was carried out by polymerase chain reaction. We found a significant association between C1173T polymorphisms and vascular calcification (odds ratio [OR] = 43, P = 0.001). The mutant T allele was also linked with higher odds of vascular calcification (OR = 8.880, 95% confidence interval [CI] = 3.1-25.4, P = 0.001) and clinically overt cardiovascular disease (OR = 4.7, 95% CI = 1.5-14.7, P = 0.005). VKORC1 G-1639A polymorphisms were not associated with vascular calcification and had lower prevalence of clinically overt cardiovascular disease (OR = 0.07, 95% CI = 0.01-0.4, P = 0.001). In patients with CKD on HD, we found that VKORC1 gene polymorphisms did have an association with prevalent cardiovascular calcification and clinically overt cardiovascular disease, C1173T polymorphisms with higher risk for disease, and G-1639A with lower risk.http://www.sjkdt.org/article.asp?issn=1319-2442;year=2016;volume=27;issue=5;spage=908;epage=915;aulast=Osman |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Noha A Osman Nevine El-Abd Mohamed Nasrallah |
spellingShingle |
Noha A Osman Nevine El-Abd Mohamed Nasrallah VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis Saudi Journal of Kidney Diseases and Transplantation |
author_facet |
Noha A Osman Nevine El-Abd Mohamed Nasrallah |
author_sort |
Noha A Osman |
title |
VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis |
title_short |
VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis |
title_full |
VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis |
title_fullStr |
VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis |
title_full_unstemmed |
VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis |
title_sort |
vkorc1 gene (vitamin k epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis |
publisher |
Wolters Kluwer Medknow Publications |
series |
Saudi Journal of Kidney Diseases and Transplantation |
issn |
1319-2442 |
publishDate |
2016-01-01 |
description |
Vitamin K is necessary for the carboxylation of clotting factors and matrix Gla protein (MGP). Vitamin K epoxide reductase (VKOR) is the enzyme responsible for recirculation of Vitamin K increasing its tissue availability. Polymorphisms of VKOR may alter the function of MGP, thereby influencing vascular calcification. We conducted this study to investigate the relationship of VKORC1 gene single nucleotide polymorphisms (SNP′s) to vascular calcification and clinically overt cardiovascular disease in chronic kidney disease (CKD) patients on hemodialysis (HD). The study included 54 CKD patients on HD. We excluded those with diabetes or on anticoagulant therapy. Vascular calcifications were measured using computerized tomography scans and roentgenograms. Prevalent clinically overt cardiovascular disease was reported based on the evidence of documented preexisting major cardiovascular events. Genotype detection for the gene VKORC1 C1173T and G-1639A polymorphisms was carried out by polymerase chain reaction. We found a significant association between C1173T polymorphisms and vascular calcification (odds ratio [OR] = 43, P = 0.001). The mutant T allele was also linked with higher odds of vascular calcification (OR = 8.880, 95% confidence interval [CI] = 3.1-25.4, P = 0.001) and clinically overt cardiovascular disease (OR = 4.7, 95% CI = 1.5-14.7, P = 0.005). VKORC1 G-1639A polymorphisms were not associated with vascular calcification and had lower prevalence of clinically overt cardiovascular disease (OR = 0.07, 95% CI = 0.01-0.4, P = 0.001). In patients with CKD on HD, we found that VKORC1 gene polymorphisms did have an association with prevalent cardiovascular calcification and clinically overt cardiovascular disease, C1173T polymorphisms with higher risk for disease, and G-1639A with lower risk. |
url |
http://www.sjkdt.org/article.asp?issn=1319-2442;year=2016;volume=27;issue=5;spage=908;epage=915;aulast=Osman |
work_keys_str_mv |
AT nohaaosman vkorc1genevitaminkepoxidereductasepolymorphismsareassociatedwithcardiovasculardiseaseinchronickidneydiseasepatientsonhemodialysis AT nevineelabd vkorc1genevitaminkepoxidereductasepolymorphismsareassociatedwithcardiovasculardiseaseinchronickidneydiseasepatientsonhemodialysis AT mohamednasrallah vkorc1genevitaminkepoxidereductasepolymorphismsareassociatedwithcardiovasculardiseaseinchronickidneydiseasepatientsonhemodialysis |
_version_ |
1725471208537849856 |